{"groups":[{"description":"Imatinib mesylate 400 mg orally daily, HES participants start with 100 mg orally daily.","id":"FG000","title":"Imatinib Mesylate"}],"periods":[{"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"125"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"125"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"recruitmentDetails":"All recruitment done at The University of Texas (UT) MD Anderson Cancer Center."}